stockportfolio.pro
Stocks / FBRX vs LAB
FBRX vs LAB
Forte Biosciences, Inc. and Standard BioTools Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Forte Biosciences, Inc. (FBRX) | Standard BioTools Inc. (LAB) | |
|---|---|---|
| Market cap | $0.4B | $0.3B |
| Revenue (latest FY) | $0 | $85.33M |
| Net income (latest FY) | $-69.38M | $-74.90M |
| Revenue growth (5y CAGR) | — | -9.2% |
| Net margin | — | -87.8% |
| Return on equity | -113.7% | -17.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open FBRX — free Open LAB — freeFrequently asked questions
Which is bigger, FBRX or LAB?
Forte Biosciences, Inc. is larger by market capitalization — $0.4B versus $0.3B.
Which grows faster, FBRX or LAB?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.